Navigation Links
AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles

terially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

CONTACT: Jenene Thomas, Senior Director, Investor Relations & CorporateCommunications, (418) 655-6420, ; PaulBurroughs, Media Relations (418) 652-8525 ext. 406, jenene.thomas@aeternazentaris.com paul.burroughs@aeternazentaris.com

Ticker Symbol: (Toronto:AEZ.),(NASDAQ-NMS:AEZS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
11. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
Post Your Comments:
(Date:9/17/2014)... , Sept. 17, 2014 ACIST Medical ... market leader of advanced imaging modalities for cardiology, showcased ... in two live cases at the Transcatheter Cardiovascular Therapeutics ... cases were presented from Medstar Washington Hospital Center ( ... University Medical Center ( New York, NY ...
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Mich., Oct. 19, 2011 Perrigo Company (Nasdaq: PRGO;TASE) ... agreement with Founder Pharma Co., Ltd., a wholly owned ... (SZSE: 000788).  Perrigo will supply infant formula manufactured in ... Pharma in China. Perrigo Chairman and CEO ...
... N.Y., Oct. 19, 2011  CureFAKtor Pharmaceuticals, LLC, a privately-held ... Focal Adhesion Kinase (FAK) inhibitors for cancer, announced today ... will present a company overview at the Biotechnology Industry ... San Francisco, CA on Wednesday, October 26 at 9:00 ...
Cached Medicine Technology:Perrigo Expands Infant Formula Distribution in China With Founder Group 2CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum 2
(Date:9/17/2014)... A new, first-of-its-kind research study was announced today ... lifestyle can impact long-term wellness and contribute to ... Prevention Research Center and funded through a $10 ... Institute Wellness Fund, WELL aims to identify lifestyle ... their health and wellness as they age. WELL ...
(Date:9/17/2014)... that guard against damage to the ends of chromosomes could ... the deadliest form of skin cancer according to ... study has uncovered an important new genetic risk factor for ... count are the strongest indicators of those most at risk ... care in the sun, as they burn more easily. , ...
(Date:9/17/2014)... 2014 Catalent Pharma Solutions, the ... development solutions for drugs, biologics and consumer health ... integrated service and technology offer based on the ... the company’s 450,000 sq. ft. Kansas City, MO ... integrate optimal formulation, development, analytical expertise, scale up ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Boston ... to create a monthly concert series, introducing young ... From the Top, America’s premier national platform celebrating ... musicians. Many of the young musicians featured will ... , “Boston Children’s Museum is fortunate to partner ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... New York City Department of,Health recently released a study ... obesity increased 17% over a two year period. With ... that they are,drinking sugar sweetened drinks with many calories, ... by drinking TrimWater, (http://www.trimwater.com )., TrimWater is a ...
... 29, 2008) Pauletta and Denzel Washington will present ... High School in Denzels hometown of Mount Vernon, N.Y. ... Pauletta and Denzel Washington Family Scholar in Neuroscience Awards ... of Neurosurgery at Cedars-Sinai Medical Center in Los Angeles. ...
... of Queensland-based Astute Nanotechnology will celebrate the,achievements ... a special presentation and cocktail,reception tomorrow Tuesday, ... for industry partners to access the,expertise and ... of Excellence for Functional,Nanomaterials (ARC CFN). , ...
... 30 AMDL, Inc. (Amex:,ADL), headquartered in ... Jilin, China, is a vertically integrated specialty,pharmaceutical ... Inc., (JPI), the Company engages in the ... supplement, and cosmetic products., AMDL today ...
... Psychemedics,Corporation (Amex: PMD ) today announced first ... The Company also announced a quarterly,dividend of $0.17 per ... 6,2008 to be paid on June 20, 2008. This ... Company,s revenue for the quarter ended March 31, 2008 ...
... Anthem,s Care Comparison Tool Gives Members in Wisconsin the ... Picture of Costs Associated with Medical Procedures, ... Blue Shield,in Wisconsin announced today the launch of its ... now nearly 3 million Anthem Blue Cross and Blue ...
Cached Medicine News:Health News:Time for New Yorkers to Drink Low-Calorie, Low-Sugar Flavored Water, TrimWater 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 3Health News:Astute Nanotechnology celebrates first year of success 2Health News:Astute Nanotechnology celebrates first year of success 3Health News:AMDL Signs MOU for 200 Store Distribution Arrangements for Goodnak Product Line 2Health News:Psychemedics Corporation Announces First Quarter Results 2Health News:Psychemedics Corporation Announces First Quarter Results 3Health News:Psychemedics Corporation Announces First Quarter Results 4Health News:Psychemedics Corporation Announces First Quarter Results 5Health News:Anthem Blue Cross and Blue Shield Introduces Industry's Most Comprehensive Transparency Initiative to Wisconsin 2Health News:Anthem Blue Cross and Blue Shield Introduces Industry's Most Comprehensive Transparency Initiative to Wisconsin 3
Plus cylinders only trial lens set....
This is a reduced form of the 100 Hue test and is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score. Kit includes 100 score pads....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Medicine Products: